Evaluating the role of Day 14 bone marrow biopsy and European LeukemiaNet risk classification in predicting overall and relapse-free survival in acute myeloid leukemia,American Journal of Hematology

当前位置： X-MOL 学术 › Am. J. Hematol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Evaluating the role of Day 14 bone marrow biopsy and European LeukemiaNet risk classification in predicting overall and relapse-free survival in acute myeloid leukemia
American Journal of Hematology ( IF 10.1 ) Pub Date : 2024-07-05 , DOI: 10.1002/ajh.27429
Metodi Balev ₁ , Victor Zibara ₁ , Grace Van Hyfte ₁ , Jonathan Feld ₁ , Marina Kremyanskaya ₁ , Michelle Becker ₁ , Alla Keyzner ₁ , Alan H Shih ₁ , Bridget Marcellino ₁ , Hannah Levavi ₁ , Lewis Silverman ₁ , John Mascarenhas ₁ , Douglas Tremblay ₁

Affiliation